Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.30 |
| ▸ | NOS1 | P29475 | 3/20 | 0.30 |
| ▸ | NOS2 | P35228 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194675 | 1.00 | — | — | |
| SCHEMBL687177 | 1.00 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL3273283 | 1.00 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL205065 | 1.00 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL495581 | 1.00 | — | — | |
| SCHEMBL4294 | 1.00 | — | — | |
| SCHEMBL206353 | 1.00 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL6575355 | 1.00 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL9808297 | 1.00 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL1432 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023117421-A1 | PAINTS CONTAINING DRIERS BASED ON VANADIUM COMPOUNDS BEARING VARIOUS ACID ANIONS | BORCHERS GMBH (DE) | 2023-06-29 | — | — | WO | claimed |
| EP-3024898-A1 | ENCAPSULATED CATALYSTS | OMG UK Technology Limited (GB) | 2016-06-01 | — | — | EP | claimed |
| WO-2015011430-A1 | ENCAPSULATED CATALYSTS | OMG UK TECHNOLOGY LIMITED (GB) | 2015-01-29 | — | — | WO | claimed |
| EP-1095031-A1 | ANTIVIRAL MACROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-05-02 | — | — | EP | claimed |
| WO-2000002870-A1 | ANTIVIRAL MACROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-01-20 | — | — | WO | claimed |
| WO-2023117421-A1 | PAINTS CONTAINING DRIERS BASED ON VANADIUM COMPOUNDS BEARING VARIOUS ACID ANIONS | BORCHERS GMBH (DE) | 2023-06-29 | — | — | WO | disclosed |
| EP-3024898-A1 | ENCAPSULATED CATALYSTS | OMG UK Technology Limited (GB) | 2016-06-01 | — | — | EP | disclosed |
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| WO-2015011430-A1 | ENCAPSULATED CATALYSTS | OMG UK TECHNOLOGY LIMITED (GB) | 2015-01-29 | — | — | WO | disclosed |
| EP-2664618-A2 | Chemokine receptor modulators | Altiris Therapeutics (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2262808-B1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2008122943-A1 | OLED WITH METAL COMPLEXES HAVING A HIGH QUANTUM EFFICIENCY | PHILIPS INTELLECTUAL PROPERTY & STANDARDS GMBH (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| EP-1456337-A1 | SUPPORT-FIXED BLEACHING CATALYST COMPLEX COMPOUNDS SUITABLE AS CATALYSTS FOR PEROXIDE COMPOUNDS | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003054128-A1 | SUPPORT-FIXED BLEACHING CATALYST COMPLEX COMPOUNDS SUITABLE AS CATALYSTS FOR PEROXIDE COMPOUNDS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2003-07-03 | — | — | WO | disclosed |
| EP-1165738-A1 | COMPOSITION AND METHOD FOR BLEACHING A SUBSTRATE | UNILEVER PLC (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000060043-A1 | COMPOSITION AND METHOD FOR BLEACHING A SUBSTRATE | UNILEVER PLC (GB) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000060044-A1 | COMPOSITION AND METHOD FOR BLEACHING A SUBSTRATE | UNILEVER PLC (GB) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172330-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | NOS3 3138/4885NOS1 3398/4885NOS2 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.